AstraZeneca stock: Omniose deal adds bacterial vaccine platform

AstraZeneca acquired Omniose on November 10, bringing the preclinical biotechnology company into its Infectious Disease Unit as a wholly owned subsidiary. The transaction adds a bioconjugation platform for bacterial vaccines after a three-year exclusive research collaboration, according to Business Wire.

The platform produces bacterial polysaccharide antigens and engineered carrier proteins within a single cell, which may simplify the development and manufacture of conjugate vaccines. AstraZeneca said the technology will support preclinical programs targeting serious bacterial infections, including threats complicated by antimicrobial resistance. Financial terms were not disclosed.

Rare Disease Pipeline Also Expands

AstraZeneca's rare-disease unit has also gained a new US indication for Ultomiris, or ravulizumab, in adults with primary immunoglobulin A nephropathy at risk of disease progression. The company's October 21 announcement said the accelerated approval covers reduction of proteinuria, while the ongoing I CAN Phase III trial is intended to assess kidney-function outcomes at week 106.

The interim trial analysis showed a placebo-adjusted 43.4 percent reduction in proteinuria at 34 weeks. The approval therefore creates a commercial opportunity while leaving longer-term kidney-function evidence as an important development milestone.

Market Context And Trading

AstraZeneca stock traded at 167.85 euros on Lang & Schwarz at 17:38 CET on Friday, November 13, 2026. The quote reflects the latest available trading reference and is not presented as a company-specific reaction to either announcement.

For broader market developments, see Current market reports.

More news and analyses on AstraZeneca stock cover the company's pipeline, clinical results and regulatory outlook.